{"id":"drug-eluting-stent-mometasone","safety":{"commonSideEffects":[{"rate":null,"effect":"In-stent restenosis"},{"rate":null,"effect":"Stent thrombosis"},{"rate":null,"effect":"Myocardial infarction"},{"rate":null,"effect":"Bleeding"}]},"_chembl":{"chemblId":"CHEMBL1201404","moleculeType":"Small molecule","molecularWeight":"427.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mometasone is a potent glucocorticoid that suppresses the inflammatory response triggered by stent placement, reducing neointimal hyperplasia and the risk of in-stent restenosis. By eluting the drug directly at the intervention site over time, local anti-inflammatory effects are achieved while minimizing systemic exposure. This approach aims to improve long-term patency and reduce the need for repeat revascularization.","oneSentence":"A drug-eluting stent that releases mometasone (a corticosteroid) locally to reduce inflammation and restenosis at the site of coronary or vascular intervention.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:35:38.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Coronary artery disease requiring percutaneous coronary intervention"},{"name":"Prevention of in-stent restenosis"}]},"trialDetails":[{"nctId":"NCT05925985","phase":"","title":"Propel Drug-Eluting Sinus Stent Family Open Cohort","status":"COMPLETED","sponsor":"Medtronic","startDate":"2023-06-01","conditions":"Chronic Rhinosinusitis (Diagnosis)","enrollment":215},{"nctId":"NCT06671561","phase":"","title":"Product Surveillance Registry; Ear, Nose and Throat - EXTEND Cohort","status":"WITHDRAWN","sponsor":"Medtronic","startDate":"2025-01-30","conditions":"Chronic Rhinosinusitis (CRS)","enrollment":""},{"nctId":"NCT03607175","phase":"PHASE2, PHASE3","title":"Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis","status":"UNKNOWN","sponsor":"Marina Boruk","startDate":"2023-07-24","conditions":"Chronic Rhinosinusitis, Nasal Polyps","enrollment":30},{"nctId":"NCT03605537","phase":"PHASE4","title":"Use of Mometasone Eluting Stent in Choanal Atresia","status":"WITHDRAWN","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-07-03","conditions":"Choanal Atresia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mometasone"],"phase":"marketed","status":"active","brandName":"Drug-eluting Stent Mometasone","genericName":"Drug-eluting Stent Mometasone","companyName":"Children's Hospital Medical Center, Cincinnati","companyId":"children-s-hospital-medical-center-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A drug-eluting stent that releases mometasone (a corticosteroid) locally to reduce inflammation and restenosis at the site of coronary or vascular intervention. Used for Coronary artery disease requiring percutaneous coronary intervention, Prevention of in-stent restenosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}